AliveCor v. Apple: ECG Patent Fight Ends in Prejudicial Dismissal After 1,746 Days
AliveCor, Inc. filed suit against Apple Computer, Inc. in the Western District of Texas, asserting three patents covering electrocardiogram monitoring technology against Apple Watch Series 4 and later devices equipped with the ECG App. After nearly five years of litigation before Judge Alan D. Albright, the parties jointly moved to dismiss the action with prejudice — each side bearing its own fees and costs.
A high-stakes wearable ECG dispute resolved on the parties’ own terms
AliveCor, Inc. — a cardiac monitoring company and holder of foundational ECG wearable patents — filed this infringement action against Apple Computer, Inc. on December 7, 2020 in the Western District of Texas before Judge Alan D. Albright. The complaint targeted Apple Watch Series 4 and later models running the ECG App, asserting three issued patents: US9572499B2, US10638941B2, and US10595731B2, all directed at electrocardiogram analysis and alerting technology for wearable devices.
The case closed on September 18, 2025, when the Court granted a Joint Motion to Dismiss with Prejudice, finding good cause on its face. Dismissal with prejudice is a final adjudication on the merits for res judicata purposes, meaning AliveCor is foreclosed from reasserting these specific claims against Apple in future litigation. The fee-neutral order — each party bearing its own costs — is consistent with a negotiated resolution rather than a unilateral capitulation, and suggests the parties reached an agreement whose full terms remain confidential.
At 1,746 days, the case ran substantially longer than the W.D. Tex. median, likely reflecting the complexity of three overlapping ECG patents, parallel PTAB proceedings that Apple initiated against AliveCor’s patents (which resulted in invalidation findings in some inter partes reviews), and broader litigation between the parties in other venues. The public record does not disclose whether any license, royalty arrangement, or cross-licensing deal accompanied the joint dismissal — a common feature of settlements in the wearable health-tech sector that parties typically keep confidential.
Filing to Dismissed with Prejudice in 1746 days
1,746 days litigated — roughly 4.8 years, well above the W.D. Tex. median for patent cases
Dismissed with prejudice: what the joint order means for both parties
Dismissal with prejudice bars AliveCor from refiling these claims
A dismissal with prejudice operates as a final judgment on the merits. Unlike a voluntary dismissal without prejudice — which preserves the right to refile — this order permanently extinguishes AliveCor’s ability to reassert US9572499B2, US10638941B2, and US10595731B2 against Apple for the same accused conduct. The joint nature of the motion, and the court’s finding of ‘good cause,’ is procedurally standard and does not indicate any fault by either party.
Res judicata appliesAliveCor surrenders further court-based enforcement of these three patents against Apple
By joining the dismissal motion, AliveCor accepts that these three ECG patents cannot be used offensively against Apple again in court. However, a with-prejudice dismissal does not extinguish the patents themselves — AliveCor may still assert them against other wearable ECG competitors. The fee-neutral order suggests AliveCor did not lose outright; a confidential settlement or licensing arrangement is consistent with this structure, though the public record does not confirm one.
Patents survive vs. third partiesApple secures permanent closure of this W.D. Tex. ECG patent front
Apple obtains a durable litigation shield: AliveCor cannot revive this action or refile on the same patents for the same Apple Watch ECG conduct. Given Apple’s parallel PTAB strategy — challenging AliveCor’s patents through inter partes review — the with-prejudice dismissal likely reflects Apple achieving sufficient IP clarity to close this district court front. Apple bearing its own costs suggests it did not extract a fee-shifting win, consistent with a negotiated exit.
No further exposure on these claimsWearable ECG IP landscape remains contested despite this closure
The dismissal resolves AliveCor’s Texas front against Apple but does not settle the broader competitive tension between dedicated cardiac monitoring devices and integrated smartwatch ECG features. AliveCor’s patents remain live assets against other wearable makers. For product teams at Samsung, Fitbit, Garmin, and other ECG-capable wearable manufacturers, these three patents — US9572499B2, US10638941B2, US10595731B2 — warrant active FTO monitoring, as AliveCor retains enforcement rights beyond this dispute.
FTO risk persists for wearable ECG sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AliveCor, Inc. | Company | Cardiac wearable technology company — holder of US9572499B2, US10638941B2, US10595731B2Search in Eureka ↗ |
| Defendant | Apple Computer, Inc. | Company | Apple Computer, Inc. — maker of Apple Watch Series 4+ with integrated ECG AppSearch in Eureka ↗ |
| Plaintiff counsel | Adam Wolfson | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Andrew M. Holmes | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff counsel | G. Blake Thompson | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff counsel | J. Mark Mann | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michelle A. Clark | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Philip Ducker | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sean San-Chul Pak | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Alston & Bird LLP | Law Firm | Representing AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Mann, Tindel & Thompson Attorneys at Law | Law Firm | Representing AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Quinn Emanuel Urquhart & Sullivan LLP | Law Firm | Representing AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff law firm | The Mann Firm | Law Firm | Representing AliveCor, Inc.Search in Eureka ↗ |
| Defendant counsel | Benjamin C. Elacqua | Attorney | Counsel for Apple Computer, Inc.Search in Eureka ↗ |
| Defendant counsel | Betty H. Chen | Attorney | Counsel for Apple Computer, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephen Burbank | Attorney | Counsel for Apple Computer, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephen E. McConnico | Attorney | Counsel for Apple Computer, Inc.Search in Eureka ↗ |
| Defendant counsel | Steven J. Wingard | Attorney | Counsel for Apple Computer, Inc.Search in Eureka ↗ |
| Defendant law firm | Desmarais LLP | Law Firm | Representing Apple Computer, Inc.Search in Eureka ↗ |
| Defendant law firm | Fish & Richardson LLP (Houston) | Law Firm | Representing Apple Computer, Inc.Search in Eureka ↗ |
| Defendant law firm | Scott, Douglass & McConnico LLP | Law Firm | Representing Apple Computer, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Alan D Albright | Judge | Texas Western District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Court’s order grants a Joint Motion to Dismiss with Prejudice and explicitly finds ‘good cause’ — a procedural threshold that is readily satisfied by mutual consent. The with-prejudice designation is the operative legal consequence: it forecloses any future action by AliveCor against Apple on these claims and patents for the same accused conduct, carrying res judicata effect. The fee-neutral provision — each party bearing its own costs — signals that no party was adjudged to have litigated in bad faith, and is consistent with a negotiated commercial resolution whose terms are not disclosed in the public record.
US9572499B2, US10638941B2 & US10595731B2 — Wearable ECG Monitoring Technology
The three asserted patents — US9572499B2, US10638941B2, and US10595731B2 — are directed at electrocardiogram monitoring technology in wearable consumer devices. They cover methods and systems for capturing ECG signals through wearable sensors, analysing cardiac rhythms in real time, detecting arrhythmias such as atrial fibrillation, and generating user alerts. The application dates span 2015 to 2019, reflecting AliveCor’s early-mover position in consumer-grade cardiac monitoring — technology that later became central to Apple Watch Series 4’s clinically cleared ECG App.
These patents sit at the intersection of medical device regulation and consumer electronics, making them strategically significant. AliveCor pioneered FDA-cleared consumer ECG hardware before Apple entered the category, and these patents represent its effort to capture IP value as the market shifted to integrated smartwatch platforms. For any wearable manufacturer integrating lead ECG, photoplethysmography-adjacent arrhythmia detection, or single-lead cardiac rhythm analysis into consumer products, AliveCor’s portfolio — and specifically these three patents — represents a material enforcement risk that has now been demonstrated by nearly five years of active litigation.
Should your product team run an FTO against AliveCor’s ECG patents?
Any company developing wearable devices with ECG functionality — including smartwatches, fitness trackers, medical-grade patches, or consumer cardiac monitors — should treat AliveCor’s portfolio as a live enforcement risk. US9572499B2, US10638941B2, and US10595731B2 have survived litigation for nearly five years against one of the world’s best-resourced defendants. Even where specific claims were narrowed or invalidated in PTAB proceedings related to Apple, residual claim scope may still read on competing products. R&D and product teams bringing ECG apps or arrhythmia detection features to market should commission a current FTO analysis before launch.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US9572499B2, US10638941B2, and US10595731B2 against your product architecture in minutes — identifying which independent claims pose the highest overlap risk, surfacing PTAB and litigation history that may have narrowed claim scope, and flagging design-around opportunities. For wearable ECG teams, Eureka can also identify the broader AliveCor portfolio beyond these three patents, helping you understand the full enforcement perimeter before committing to a product roadmap.
Run a freedom-to-operate analysis on US9572499B2 to assess your product’s exposure
Run FTO in Eureka →Similar ECG wearable patent cases in W.D. Tex. and related venues
Browse comparable patent infringement actions involving wearable ECG, cardiac monitoring technology, and Apple Watch before the Western District of Texas and related courts.
What this case signals for the wearable ECG and cardiac health-tech IP landscape
Nearly five years of W.D. Tex. litigation between AliveCor and Apple carries lessons for any company building ECG features into consumer wearables.
Parallel PTAB proceedings can reshape district court leverage significantly
This case unfolded alongside inter partes review challenges Apple filed against AliveCor’s ECG patents at the PTAB. When PTAB proceedings invalidate or narrow asserted claims, the district court calculus shifts materially. Companies facing multi-patent assertions should evaluate concurrent IPR filing as a cost-effective way to alter negotiating leverage before trial.
Joint dismissal with prejudice is a signal — not a concession — in complex patent disputes
The fee-neutral, joint structure of this dismissal is inconsistent with either party claiming a clear courtroom win. It is more consistent with a confidential commercial resolution. Patent professionals should read with-prejudice joint dismissals in tech cases as likely settlement signals, not as admissions of infringement or invalidity by either party.
AliveCor v Apple — key questions answered
The case was dismissed with prejudice by joint motion on September 18, 2025, after 1,746 days of litigation. Judge Alan D. Albright granted the Joint Motion to Dismiss with Prejudice, with each party bearing its own fees and costs. AliveCor cannot refile these claims against Apple.
AliveCor asserted three patents: US9572499B2, US10638941B2, and US10595731B2. All three relate to wearable electrocardiogram monitoring technology — covering ECG signal capture, arrhythmia detection, and cardiac alerting systems. The accused product was Apple Watch Series 4 and later devices running the ECG App.
Dismissal with prejudice operates as a final judgment on the merits for res judicata purposes. AliveCor cannot refile suit against Apple asserting these three patents for the same accused conduct. However, the patents themselves remain in force — AliveCor retains the right to assert them against other wearable ECG manufacturers.
The public record shows a joint motion to dismiss with prejudice, with each side bearing its own fees and costs — a structure consistent with a negotiated settlement. However, the Court’s order does not confirm or disclose any settlement terms, license, or payment. The existence and terms of any underlying agreement remain confidential.
Judge Albright of the Western District of Texas became one of the most prominent patent judges in the US, attracting a high volume of patent filings due to plaintiff-friendly scheduling. This case’s 1,746-day duration — longer than the W.D. Tex. median — suggests significant procedural complexity, likely involving claim construction hearings, PTAB stay motions, and expert discovery typical of multi-patent disputes against well-resourced defendants.
PatSnap Eureka searches patents and litigation data to answer instantly.